UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): June 3, 2007

                           ARIAD Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)


      Delaware                       0-21696                    22-3106987
  (State or other                  (Commission               (I.R.S. Employer
   jurisdiction                    File Number)             Identification No.)
 of incorporation)


        26 Landsdowne Street, Cambridge, Massachusetts            02139
        (Address of principal executive offices)                (Zip Code)


       Registrant's telephone number, including area code: (617) 494-0400


                                 Not Applicable
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

|_|  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))




ITEM 8.01         Other Events.

               In a press release dated June 3, 2007, ARIAD Pharmaceuticals,
               Inc. announced that AP23573 - its novel mTOR inhibitor -
               demonstrated efficacy and was well tolerated as a single agent in
               a multi-center Phase 2 trial in metastatic endometrial cancer
               involving 45 patients, all of whom had progressive disease. The
               primary end-point of the trial - evidenced by significant
               clinical-benefit response (CBR) rates - was achieved. Twenty-nine
               percent (29%) of patients had a CBR - tumor regression or disease
               stabilization - including 10% with partial responses.

               A copy of the press release is filed herewith as Exhibit 99.1 and
               the information contained therein is incorporated by reference
               into this Item 8.01 of this Current Report on Form 8-K.




ITEM 9.01         Financial Statements and Exhibits.

                 (c) The following exhibits are filed with this report

                     Exhibit
                     Number             Description
                     ------             -----------
                     99.1               Press release dated June 3, 2007




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                           ARIAD Pharmaceuticals, Inc.



                           By:      /s/ Edward M. Fitzgerald
                              --------------------------------------------------
                                    Edward M. Fitzgerald
                                    Senior Vice President, Finance and Corporate
                                    Operations, Chief Financial Officer


Date:    June 4, 2007




                                  EXHIBIT INDEX
                                  -------------

Exhibit
Number            Description
------            -----------
99.1              Press release dated June 3, 2007